Cargando…
Cost-effectiveness of apixaban vs. current standard of care for stroke prevention in patients with atrial fibrillation
AIMS: Warfarin, a vitamin K antagonist (VKA), has been the standard of care for stroke prevention in patients with atrial fibrillation (AF). Aspirin is recommended for low-risk patients and those unsuitable for warfarin. Apixaban is an oral anticoagulant that has demonstrated better efficacy than wa...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4104492/ https://www.ncbi.nlm.nih.gov/pubmed/24513791 http://dx.doi.org/10.1093/eurheartj/ehu006 |
_version_ | 1782327266075738112 |
---|---|
author | Dorian, Paul Kongnakorn, Thitima Phatak, Hemant Rublee, Dale A. Kuznik, Andreas Lanitis, Tereza Liu, Larry Z. Iloeje, Uchenna Hernandez, Luis Lip, Gregory Y.H. |
author_facet | Dorian, Paul Kongnakorn, Thitima Phatak, Hemant Rublee, Dale A. Kuznik, Andreas Lanitis, Tereza Liu, Larry Z. Iloeje, Uchenna Hernandez, Luis Lip, Gregory Y.H. |
author_sort | Dorian, Paul |
collection | PubMed |
description | AIMS: Warfarin, a vitamin K antagonist (VKA), has been the standard of care for stroke prevention in patients with atrial fibrillation (AF). Aspirin is recommended for low-risk patients and those unsuitable for warfarin. Apixaban is an oral anticoagulant that has demonstrated better efficacy than warfarin and aspirin in the ARISTOTLE and AVERROES studies, respectively, and causes less bleeding than warfarin. We evaluated the potential cost-effectiveness of apixaban against warfarin and aspirin from the perspective of the UK payer perspective. RESULTS AND METHODS: A lifetime Markov model was developed to evaluate the pharmacoeconomic impact of apixaban compared with warfarin and aspirin in VKA suitable and VKA unsuitable patients, respectively. Clinical events considered in the model include ischaemic stroke, haemorrhagic stroke, intracranial haemorrhage, other major bleed, clinically relevant non-major bleed, myocardial infarction, cardiovascular hospitalization and treatment discontinuations; data from the ARISTOTLE and AVERROES trials and published mortality rates and event-related utility rates were used in the model. Apixaban was projected to increase life expectancy and quality-adjusted life years (QALYs) compared with warfarin and aspirin. These gains were expected to be achieved at a drug acquisition-related cost increase over lifetime. The estimated incremental cost-effectiveness ratio was £11 909 and £7196 per QALY gained with apixaban compared with warfarin and aspirin, respectively. Sensitivity analyses indicated that results were robust to a wide range of inputs. CONCLUSIONS: Based on randomized trial data, apixaban is a cost-effective alternative to warfarin and aspirin, in VKA suitable and VKA unsuitable patients with AF, respectively. |
format | Online Article Text |
id | pubmed-4104492 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-41044922014-07-21 Cost-effectiveness of apixaban vs. current standard of care for stroke prevention in patients with atrial fibrillation Dorian, Paul Kongnakorn, Thitima Phatak, Hemant Rublee, Dale A. Kuznik, Andreas Lanitis, Tereza Liu, Larry Z. Iloeje, Uchenna Hernandez, Luis Lip, Gregory Y.H. Eur Heart J Basic Science AIMS: Warfarin, a vitamin K antagonist (VKA), has been the standard of care for stroke prevention in patients with atrial fibrillation (AF). Aspirin is recommended for low-risk patients and those unsuitable for warfarin. Apixaban is an oral anticoagulant that has demonstrated better efficacy than warfarin and aspirin in the ARISTOTLE and AVERROES studies, respectively, and causes less bleeding than warfarin. We evaluated the potential cost-effectiveness of apixaban against warfarin and aspirin from the perspective of the UK payer perspective. RESULTS AND METHODS: A lifetime Markov model was developed to evaluate the pharmacoeconomic impact of apixaban compared with warfarin and aspirin in VKA suitable and VKA unsuitable patients, respectively. Clinical events considered in the model include ischaemic stroke, haemorrhagic stroke, intracranial haemorrhage, other major bleed, clinically relevant non-major bleed, myocardial infarction, cardiovascular hospitalization and treatment discontinuations; data from the ARISTOTLE and AVERROES trials and published mortality rates and event-related utility rates were used in the model. Apixaban was projected to increase life expectancy and quality-adjusted life years (QALYs) compared with warfarin and aspirin. These gains were expected to be achieved at a drug acquisition-related cost increase over lifetime. The estimated incremental cost-effectiveness ratio was £11 909 and £7196 per QALY gained with apixaban compared with warfarin and aspirin, respectively. Sensitivity analyses indicated that results were robust to a wide range of inputs. CONCLUSIONS: Based on randomized trial data, apixaban is a cost-effective alternative to warfarin and aspirin, in VKA suitable and VKA unsuitable patients with AF, respectively. Oxford University Press 2014-07-21 2014-02-09 /pmc/articles/PMC4104492/ /pubmed/24513791 http://dx.doi.org/10.1093/eurheartj/ehu006 Text en © The Author 2014. Published by Oxford University Press on behalf of the European Society of Cardiology. http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Basic Science Dorian, Paul Kongnakorn, Thitima Phatak, Hemant Rublee, Dale A. Kuznik, Andreas Lanitis, Tereza Liu, Larry Z. Iloeje, Uchenna Hernandez, Luis Lip, Gregory Y.H. Cost-effectiveness of apixaban vs. current standard of care for stroke prevention in patients with atrial fibrillation |
title | Cost-effectiveness of apixaban vs. current standard of care for stroke prevention in patients with atrial fibrillation |
title_full | Cost-effectiveness of apixaban vs. current standard of care for stroke prevention in patients with atrial fibrillation |
title_fullStr | Cost-effectiveness of apixaban vs. current standard of care for stroke prevention in patients with atrial fibrillation |
title_full_unstemmed | Cost-effectiveness of apixaban vs. current standard of care for stroke prevention in patients with atrial fibrillation |
title_short | Cost-effectiveness of apixaban vs. current standard of care for stroke prevention in patients with atrial fibrillation |
title_sort | cost-effectiveness of apixaban vs. current standard of care for stroke prevention in patients with atrial fibrillation |
topic | Basic Science |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4104492/ https://www.ncbi.nlm.nih.gov/pubmed/24513791 http://dx.doi.org/10.1093/eurheartj/ehu006 |
work_keys_str_mv | AT dorianpaul costeffectivenessofapixabanvscurrentstandardofcareforstrokepreventioninpatientswithatrialfibrillation AT kongnakornthitima costeffectivenessofapixabanvscurrentstandardofcareforstrokepreventioninpatientswithatrialfibrillation AT phatakhemant costeffectivenessofapixabanvscurrentstandardofcareforstrokepreventioninpatientswithatrialfibrillation AT rubleedalea costeffectivenessofapixabanvscurrentstandardofcareforstrokepreventioninpatientswithatrialfibrillation AT kuznikandreas costeffectivenessofapixabanvscurrentstandardofcareforstrokepreventioninpatientswithatrialfibrillation AT lanitistereza costeffectivenessofapixabanvscurrentstandardofcareforstrokepreventioninpatientswithatrialfibrillation AT liularryz costeffectivenessofapixabanvscurrentstandardofcareforstrokepreventioninpatientswithatrialfibrillation AT iloejeuchenna costeffectivenessofapixabanvscurrentstandardofcareforstrokepreventioninpatientswithatrialfibrillation AT hernandezluis costeffectivenessofapixabanvscurrentstandardofcareforstrokepreventioninpatientswithatrialfibrillation AT lipgregoryyh costeffectivenessofapixabanvscurrentstandardofcareforstrokepreventioninpatientswithatrialfibrillation |